HIV Guidelines

HIV Treatment and Management

HIV Testing and Prevention

HIV Guidelines

References

  1. Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention
    in men who have sex with men. N Engl J Med 2010;363:2587-99.
  2. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1
    infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet
    2016;387:53-60.
  3. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV
    transmission in Botswana. N Engl J Med 2012;367:423–34.
  4. Deutsch MB, Glidden DV, Sevelius J, et al; iPrEx investigators. HIV pre-exposure prophylaxis in
    transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV 2015;2:e512–9.
  5. Choopanya K, Martin M, Suntharasamai P, et al; Bangkok Tenofovir Study Group. Antiretroviral prophylaxis
    for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir study): a randomised,
    double-blind, placebo-controlled phase 3 trial. Lancet 2013;381:2083–90.
  6. World Health Organization. Technical brief. What’s the 2+1+1? Event-driven oral pre-exposure prophylaxis
    to prevent HIV for men who have sex with men: update to WHO’s recommendation on oral PrEP. July 2019. Available
    at: https://apps.who.int/iris/bitstream/handle/10665/325955/WHO-CDS-HIV-19.8-eng.pdf?ua=1 (last
    accessed 3 September 2019).
  7. Hosek SG, Rudy B, Landovitz R, et al; Adolescent Trials Network (ATN) for HIVAIDS Interventions. An HIV
    preexposure prophylaxis demonstration project and safety study for young MSM. J Acquir Immune Defic Syndr
    2017;74:21-9.
  8. Hosek SG, Landovitz RJ, Kapogiannis B, et al. Safety and feasibility of antiretroviral preexposure
    prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States. JAMA Pediatr
    2017;171:1063-71.
  9. Noret M, Balavoine S, Pintado C, et al. Daily or on-demand oral tenofovir disoproxil
    fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France. AIDS
    2018;32:2161–9.
  10. Molina JM, Charreau I, Spire B, et al; ANRS IPERGAY Study Group. Efficacy, safety, and effect on sexual
    behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort
    study. Lancet HIV 2017;4:e402–10.
  11. Molina JM, Ghosn J, Algarte‐Génin M, et al; ANRS Study Group. Incidence of HIV‐infection with daily or
    on‐demand PrEP with TDF/FTC in Paris area. Update from the ANRS Prévenir Study. Abstract TUAC0202. Oral
    abstracts of the 10th IAS Conference on HIV Science, 21-24 July 2019, Mexico City, Mexico. J Int AIDS Soc
    2019;22 Suppl 5:e25327.
  12. Molina JM, Capitant C, Spire B, et al; ANRS IPERGAY Study Group. On-demand preexposure prophylaxis in
    men at high risk for HIV-1 infection. N Engl J Med 2015;373:2237-46.
  13. Antoni G, Tremblay C, Charreau I, et al. On-demand PrEP with TDF/FTC remains highly effective among MSM
    with infrequent sexual intercourse: a sub-study of the ANRS IPERGAY trial. Abstract TUAC0102. International AIDS
    Society (IAS) Conference on HIV Science. July 2017; Paris, France.
  14. Liegeon G, Antoni G, Pialoux G, et al. Changes in kidney function among MSM initiation on-demand TDF/FTC
    for HIV PrEP. Abstract Number: 960. Conference on Retroviruses and Opportunistic Infections (CROI); 4-7 March
    2019; Seattle, Washington.
  15. Grant RM, Mannheimer S, Hughes JP, et al. Daily and nondaily oral preexposure prophylaxis in men and
    transgender women who have sex with men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT
    Study. Clin Infect Dis 2018;66:1712–21.
  16. PrEP in Europe [website]. Intermittent PrEP. Available at: www.prepineurope.org/en/faqs/does-prep-work/intermittent-prep/ (last
    accessed 3 September 2019).
  17. Vaccher SJ, Gianacas C, Templeton DJ, et al; PRELUDE Study Team. Baseline preferences for daily,
    event-driven, or periodic HIV pre-exposure prophylaxis among gay and bisexual men in the PRELUDE Demonstration
    Project. Front Public Health 2017;5:341.
  18. Cornelisse VJ, Lal L, Price B, et al. Interest in switching to on-demand pre-exposure prophylaxis (PrEP)
    among Australian users of daily PrEP: an online survey. Open Forum Infect Dis 2019;6:ofz287.
  19. Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis
    for all populations. AIDS 2016;30:1973–83.
  20. Buttram ME, Kurtz SP. Preliminary evidence of HIV seroconversion among HIV-negative men who have sex
    with men taking non-prescribed antiretroviral medication for HIV prevention in Miami, Florida, USA. Sex Health
    2017;14:193-5.
  21. Gilead Sciences. Full prescribing information. Issued June 2013. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2013/021752s035lbl.pdf (last
    accessed 4 September 2019).
  22. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral
    agents in adults and adolescents with HIV. Department of Health and Human Services. Last updated 10 July 2019.
    Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (last
    accessed 4 September 2019).
  23. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV
    incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis 2014;14:820–9.
  24. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues:
    implications for prevention of HIV-1 transmission. Sci Transl Med 2011;3:112re4.
  25. Anderson PL. Pharmacology considerations for HIV prevention [presentation]. 13th International Workshop
    on Clinical Pharmacology of HIV. Barcelona, Spain; April 2012. Available at: http://regist2.virology-education.com/2012/13hivpk/docs/16_Anderson.pdf (last
    accessed 4 September 2019).
  26. Anderson PL, Kiser JJ, Gardner EM, et al. Pharmacological considerations for tenofovir and emtricitabine
    to prevent HIV infection. J Antimicrob Chemother 2011;66:240-50.
  27. Cottrell ML, Yang KH, Prince HM, et al. A translational pharmacology approach to predicting outcomes of
    preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without
    emtricitabine. J Infect Dis 2016;214:55-64.
  28. Cottrell L, Yang KH, Prince HMA, et al; A Translational Pharmacology Approach to Predicting Outcomes of
    Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without
    Emtricitabine. The Journal of Infectious Diseases 2016;214:55–64
  29. Glidden DV, Anderson PL, Grant RM. Pharmacology supports “on-demand” PrEP. Lancet HIV. 2016:
    3(9):e405-e406
  30. Cornelisse VJ, Wright EJ, Fairley CK, McGuinness SL. Sexual safety and HIV prevention in travel
    medicine: Practical considerations and new approaches. Travel Med Infect Dis 2019;28:68-73.
  31. Seifert SM, Glidden DV, Meditz AL, et al. Dose response for starting and stopping HIV preexposure
    prophylaxis for men who have sex with men. Clin Infect Dis 2015;60:804-10.
HIV Guidelines

HIV Treatment and Management

HIV Testing and Prevention

Frequently used tools